

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians

Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Thomas D. Denberg, MD, PhD; Donald E. Casey, Jr., MD, MPH, MBA; Mary Ann Forciea, MD; Douglas K. Owens, MD, MS; and Paul Shekelle, MD, PhD, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians*

Description: The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment.

Methods: Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS (2006). The literature search was updated by searching for articles in MEDLINE and EMBASE published between May 2007 and April 2009. Searches were limited to English-language publications. This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system.

Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men

who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence).

Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence).

Recommendation 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).

Ann Intern Med. 2009;151:* * * FILL THIS IN * * *
For author affiliations, see end of text.

www.annals.org

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain penile erection sufficient for satisfactory sexual performance (1). Erectile dysfunction lasting for 3 months is considered a reasonable length of time to warrant evaluation and consideration of treatment. Erectile dysfunction is a common disorder of male sexual function and affects all age groups, especially people with advanced age, diabetes, vascular diseases, psychiatric disorders, and possibly hypogonadism (1–4). With the aging general population and increased life expectancy, combined with the high prevalence of diabetes and cardiovascular disease, the health care burden and quality-of-life issues associated with ED are projected to be substantial (5). In 1995, more than 152 million men worldwide were estimated to have experienced ED. The prevalence of ED is predicted to be approximately 322 million worldwide by the year 2025 (6). Estimates from the National Health and Nutrition Examination Survey suggested that the cost of

treatment of ED in the United States could reach \$15 billion if all affected men sought care (7).

The purpose of this guideline is to present the available evidence on the hormonal testing and pharmacologic management of ED. The target audience for this guideline is all clinicians, and the target population is all men with ED. Recommendations are based on the systematic evidence review by Tsertsvadze and colleagues (8) and the

See also:

Print

Related article 1
Summary for Patients 2

Web-Only

CME quiz
Conversion of graphics into slides

* This paper, written by Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Thomas D. Denberg, MD, PhD; Donald E. Casey Jr., MD, MPH, MBA; Mary Ann Forciea, MD; Douglas K. Owens, MD, MS; and Paul Shekelle, MD, PhD, was developed for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians (ACP): Paul Shekelle, MD, PhD (Chair); Roger Chou, MD; Paul Dallas, MD; Thomas D. Denberg, MD, PhD; Mary Ann Forciea, MD; Robert H. Hopkins Jr., MD; Linda Humphrey, MD, MPH; David B. Nash, MD, MBA; Douglas K. Owens, MD, MS; and Donna Sweet, MD. Approved by the ACP Board of Regents on 11 July 2009. This article was published at www.annals.org on 20 October 2009.

evidence report by the Agency for Healthcare Research and Quality–sponsored University of Ottawa Evidence-based Practice Center (5). Erectile dysfunction may be caused by chronic diseases, such as obesity, hypertension, dyslipidemia, and cardiovascular disease, or smoking; medications; psychosocial factors; and hormonal abnormalities. This guideline addresses only the utility of hormonal testing and treatment of ED. Such treatments as vacuum constriction devices, intraurethral suppositories, intracavernosal injections, and psychotherapy were not included in the evidence review and are not addressed in this guideline.

METHODS

The databases used for the literature search included MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS (2006). The literature search was limited to studies published in English and scanning of reference lists of retrieved publications. The literature search was updated by searching for articles on MEDLINE and EMBASE published between May 2007 and April 2009.

Two persons independently reviewed abstracts and relevant full-text articles regarding study, study population, and treatment characteristics. Disagreements were discussed and resolved by consensus. The reviewers excluded reviews, pooled analysis, editorials, commentaries, and letters. To assess the relative benefits and harms of pharmacologic treatments for ED, eligible studies included randomized, controlled trials (RCTs) of pharmacologic ED treatments in men aged 18 years or older with ED. To assess the clinical value of routine hormonal blood tests in men with ED, eligible studies were those reporting prevalence of hypogonadism, hyperprolactinemia, or both in men with ED and RCTs comparing hormone treatment alone or in combination versus control in men with ED. For adverse events, data abstracted included the number of patients with any adverse event, specific adverse events, withdrawals due to adverse events, serious adverse events, and serious cardiovascular adverse events. To assess the risks for nonarteritic anterior ischemic optic neuropathy (NAION) in men receiving phosphodiesterase-5 (PDE-5) inhibitors, eligible studies included RCTs; nonrandomized, controlled trials; and observational studies. Treatments not generally prescribed by primary care physicians, such as vacuum constriction devices, intraurethral suppositories, intracavernosal injections, or psychotherapy, were considered beyond the scope of this guideline.

This guideline rates the evidence and recommendations by using the American College of Physicians' guideline grading system, which is a slightly modified version of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system (Table).

Table. The American College of Physicians' Guideline Grading System*

Quality of Evidence	Strength of Recommendation	
	Benefits Clearly Outweigh Risks and Burden OR Risks and Burden Clearly Outweigh Benefits	Benefits Finely Balanced With Risks and Burden
High	Strong	Weak
Moderate	Strong	Weak
Low	Strong	Weak
	Insufficient evidence to determine net benefits or risks	

* Adopted from the classification developed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) workgroup.

The objective of this guideline is to synthesize the evidence for the following key questions:

Key question 1: What is the clinical utility of routine hormonal blood tests—testosterone and prolactin—in identifying and affecting therapeutic outcomes for treatable causes of ED?

Key question 2: What are the benefits of pharmaceutical treatments for patients with ED?

Key question 3: What are the harms of the pharmaceutical treatments for patients with ED?

CLINICAL UTILITY OF ROUTINE HORMONAL DIAGNOSTIC TESTS

Evidence was gathered from 29 studies, of which 28 reported measurement of testosterone (9–37) and 10 reported measurement of prolactin (9, 10, 12, 14, 15, 20, 22, 27, 28, 38). Mean age of participants ranged from 47 to 60 years. The overall quality of evidence was rated as low because of between-study variability in study populations, varying hormone measurement methods, and prevalence rates of hormonal abnormalities.

The prevalence of low total testosterone levels (12, 23, 34, 35), low free testosterone levels (21, 29), and hyperprolactinemia (14, 27, 28) in men with ED varied widely across studies. The prevalence of low testosterone levels (defined in the studies as <288 ng/dL [<9.9 nmol/L] or <9.0 pg/mL [<31.2 pmol/L]) in men with ED varied from 12.5% to 35% in different studies (20, 21, 31). This variability may be due to between-study differences in study population characteristics, hormonal measurement methods, diagnostic criteria for ED or hormonal abnormalities, or a combination of these factors. Because evidence was insufficient to determine whether men with ED had a higher prevalence of hypogonadism or hyperprolactinemia than men without ED (31, 32), the value of routine hormonal testing for the evaluation of ED is unclear.

BENEFITS OF PHARMACOLOGIC TREATMENT

Oral PDE-5 Inhibitors

Evidence was gathered from 130 RCTs that evaluated oral PDE-5 inhibitors, alone or combination (72 RCTs of sildenafil [39–107], 27 RCTs of vardenafil [13, 108–133], 28 RCTs of tadalafil [134–161], 2 RCTs of mirodenafil [156, 157], and 1 RCT of udenafil [162]), and 4 RCTs with head-to-head comparisons of PDE-5 inhibitors (163–166). Treatment duration for most trials was 12 months, and 85% of the trials did not report treatment allocation concealment.

PDE-5 Inhibitor Versus Placebo

Successful Sexual Intercourse. High-quality evidence from RCTs showed that PDE-5 inhibitors improved successful sexual intercourse. The weighted mean percentage of successful sexual intercourse attempts was 69% (range, 52% to 85%) for sildenafil versus 35.5% (range, 19% to 68%) for placebo (41, 43, 44, 47, 48, 57, 66, 69, 78, 83, 84, 90, 93, 100, 102, 103), 68% (range, 50% to 88%) for vardenafil versus 35% (range, 20% to 40%) for placebo (13, 108, 110, 112, 115, 116, 121, 123, 124, 126, 127, 130, 132), and 69% (range, 50% to 85%) for tadalafil versus 33% (range, 23% to 52%) for placebo (136, 137, 139–141, 143, 144, 147, 149, 153–157, 159). In trials enrolling men with a wide spectrum of diseases, corresponding values were 69% versus 36% (41, 43, 44, 47, 48, 57, 66, 69, 78, 83, 84, 90, 93, 100, 102, 103, 108), 68% versus 35% (13, 110, 112, 115, 116, 121, 123, 124, 126, 127, 130–132), and 69% versus 33% (136, 137, 139–141, 143, 144, 147, 149, 153–157, 159).

Improvement in Erections. High-quality evidence indicated that all 5 agents (sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil) improved erections (range, 73% to 88%) compared with placebo (range, 26% to 32%) (13, 40–43, 47–49, 51, 54–58, 60, 62, 64, 66, 69–71, 74, 77–80, 82–84, 91, 95, 99, 100, 106, 109–113, 115, 116, 118, 120, 122–124, 130, 132, 136–144, 146, 147, 149, 153–157, 161, 162, 167, 168). Men assigned to PDE-5 inhibitors experienced improved erections compared with placebo in trials limited to patients with specific medical conditions, such as diabetes (42, 53, 54, 58, 60, 104, 107, 109, 126, 127, 146, 161), depression (40, 52, 66, 91, 122), cardiovascular disease (45, 61, 64, 74, 80, 82, 95, 120, 133), prostate cancer (73, 96, 101, 111, 131, 142, 158, 169), multiple sclerosis (62, 106), colorectal cancer (71), schizophrenia (92), liver failure (63), and renal failure (89, 128).

Dose. Improvement in erectile functioning was related to higher dose for sildenafil (50 mg vs. 25 mg but not 100 mg vs. 50 mg) and vardenafil (20 mg vs. 10 mg vs. 5 mg) but not for tadalafil (20 mg vs. 10 mg vs. 5 mg) (53, 57, 74, 77, 109, 113, 114, 116, 118, 127, 161, 162, 167, 168).

PDE-5 Inhibitor Versus Non-PDE-5 Inhibitor

Sildenafil was more effective than non-PDE-5 inhibitor treatments, such as sublingual apomorphine, psychotherapy, continuous positive airway pressure, phentolamine, and alfuzosin, in improving erectile function (170–174), frequency of penile penetration or erectile maintenance, and percentage of successful intercourse attempts (175–179).

PDE-5 Inhibitor Plus Non-PDE-5 Inhibitor Versus PDE-5 Inhibitor

Sildenafil combined with other ED therapies (such as psychotherapy, dihydroergotamine, cabergoline, atorvastatin, quinapril, and alfuzosin) resulted in greater improvements in erectile function and frequency of penile penetration or maintenance of erection than did sildenafil alone (169, 175, 179–185).

PDE-5 Inhibitor Versus PDE-5 Inhibitor

Successful Sexual Intercourse. Low-quality studies comparing tadalafil and sildenafil provided insufficient evidence to determine whether 1 treatment was more effective than the other (163).

Improvement in Erections. Evidence from 2 low-quality RCTs comparing tadalafil and sildenafil was insufficient to determine the effectiveness of 1 drug over the other (163, 166).

Hormonal Treatments

Evidence was gathered from 15 RCTs that evaluated the efficacy of hormonal therapy (oral, intramuscular, gel, cream, or patch testosterone) on ED outcomes in hypogonadal men (186–200).

Hormonal Therapy Versus Placebo

Successful Sexual Intercourse. Low-quality evidence was insufficient to show whether testosterone was more effective than placebo (193, 200). In 1 low-quality trial, gel testosterone (50 to 100 mg) but not patch testosterone modestly improved the frequency of successful sexual intercourse compared with placebo (187).

Improvement in Erections. Low-quality evidence was insufficient to determine whether testosterone was more effective than placebo (186, 189, 191, 193, 195, 197).

Hormonal Therapy Plus PDE-5 Inhibitor Versus PDE-5 Inhibitor

Successful Sexual Intercourse. Low-quality evidence was insufficient to determine whether testosterone plus a PDE-5 inhibitor (sildenafil) was more effective than a PDE-5 inhibitor (sildenafil) and placebo in improving frequency or percentage of successful sexual intercourse attempts (188, 190).

Improvement in Erections. Low-quality evidence was insufficient to determine whether testosterone plus a

PDE-5 inhibitor (sildenafil) was more effective than a PDE-5 inhibitor (sildenafil) and placebo (188, 190, 194).

HARMS OF PHARMACOLOGIC TREATMENT

Oral PDE-5 Inhibitors

PDE-5 Inhibitor Versus Placebo

High-quality evidence showed that men receiving PDE-5 inhibitors are more likely to have at least 1 adverse event compared with placebo. However, the incidence for more serious adverse events was less than 2%, with no difference between PDE-5 inhibitors and placebo. The most common adverse effects were headache, flushing, rhinitis, and dyspepsia. Less common adverse effects were visual disturbances, myalgia, nausea, diarrhea, vomiting, dizziness, and chest pain.

PDE-5 Inhibitor Versus Non-PDE-5 Inhibitor

Sildenafil was associated with fewer adverse events than non-PDE-5 inhibitors (170–179).

PDE-5 Inhibitor Plus Non-PDE-5 Inhibitor Versus

PDE-5 Inhibitor

Sildenafil was associated with fewer adverse events than PDE-5 inhibitors combined with non-PDE-5 inhibitors (169, 175, 179, 181–185).

PDE-5 Inhibitor Versus PDE-5 Inhibitor

Very-low-quality evidence showed that adverse events did not statistically significantly differ among men taking sildenafil, tadalafil, and vardenafil (163–166).

NAION

Nonarteritic anterior ischemic optic neuropathy is defined as ischemic optic neuropathy in the absence of temporal arteritis and polymyalgia rheumatica, and “possible” NAION is defined as papillitis, optic neuritis, or both in the absence of temporal arteritis, polymyalgia rheumatica, and previous optic neuropathies. Very-low-quality evidence evaluating the association of NAION with the use of PDE-5 inhibitors showed that among 4 million veterans aged 50 years or older, PDE-5 inhibitors were not associated with an increased risk for NAION (absolute risk, 4.6 cases per 10 000 men per year; relative risk, 1.02 [95% CI, 0.92 to 1.12]); however, PDE-5 inhibitors were associated with an increased risk for possible NAION (absolute risk, 2.4 cases per 10 000 men per year; relative risk, 1.34 [CI, 1.17 to 1.55]) (201).

Priapism

Trials evaluated for this guideline did not report priapism. Prolonged erection and priapism were reported infrequently during postmarketing surveillance (202).

Contraindications

Concurrent use, regularly or intermittently, of nitrates in any form (for example, nitroglycerin and isosorbide di-

nitrate) is a contraindication for oral PDE-5 inhibitor therapy.

Hormonal Treatments

Hormonal Therapy Versus Placebo

Very-low-quality evidence showed that adverse events did not differ between oral or gel testosterone and placebo (187, 193, 200). The levels of prostate-specific antigen were similar in testosterone and placebo groups in 3 trials reporting these data (189, 198, 199).

Hormonal Therapy Plus PDE-5 Inhibitor Versus PDE-5 Inhibitor

Low-quality evidence showed that the incidence of adverse events was low and did not differ between sildenafil alone versus sildenafil plus patch, gel, or oral testosterone (188, 190, 194). Prostate-specific antigen levels were not significantly higher in the sildenafil plus testosterone groups than in sildenafil groups in 2 trials reporting these data (190, 194).

SUMMARY

The evidence regarding the utility of hormonal blood tests in identifying and affecting therapeutic outcomes for treatable causes of ED was inconclusive. The evidence demonstrated clinical benefit associated with the use of PDE-5 inhibitors regardless of the cause (such as diabetes, depression, or prostate cancer) or baseline severity of ED. The magnitude of benefit increased with severity of ED. Higher doses of sildenafil and vardenafil were associated with a modestly greater magnitude of benefit with respect to erectile function; however, this was not true for tadalafil. Overall, PDE-5 inhibitors were relatively well tolerated and were associated with mild or moderate adverse events. The incidence of adverse events did not significantly differ among the various PDE-5 inhibitors. Evidence was insufficient to determine whether PDE-5 inhibitors are associated with an increased risk for NAION.

FUTURE RESEARCH

The quality of reporting primary studies should be improved. Authors reporting trials in journals that publish ED-related research should consider using the CONSORT (Consolidated Standards of Reporting Trials) Statement as a reporting guide. Some studies evaluated the dose-response effect of PDE-5 inhibitors with respect to efficacy and harms; however, more high-quality studies are needed. The evidence regarding the incidence of adverse events was limited and inconclusive, and more high-quality head-to-head trials are needed to explore differences in adverse events, especially severe adverse events. The evidence regarding the utility of routine hormonal blood tests was inconclusive given the limited number of studies and various methodological issues and needs to be further developed.

Figure. The American College of Physicians guideline on hormonal testing and pharmacologic treatment of erectile dysfunction.

ACP Clinical Practice[®]
 American College of Physicians
GUIDELINES

Summary of the American College of Physicians Guideline on Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction	
Disease/condition	Erectile dysfunction
Target audience	Internists, family physicians, other clinicians
Target patient population	Men with erectile dysfunction
Interventions	Hormonal testing; oral PDE-5 inhibitors; hormonal therapy
Outcomes	Successful sexual intercourse and improvement in erections
Recommendations	<p><i>Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence).</i></p> <p><i>Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence).</i></p> <p><i>Recommendation 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).</i></p>
Clinical considerations	<p>This guideline refers to patients with erectile dysfunction. There may be other reasons to perform hormonal testing.</p> <p>Clinicians should be aware of the cautions related to PDE-5 inhibitor use when prescribing these agents.</p> <p>Nonpharmacologic treatment of erectile dysfunction is beyond the scope of this guideline.</p>

PDE-5 = phosphodiesterase-5.

RECOMMENDATIONS

Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence).

Treatment with an oral PDE-5 inhibitor demonstrated statistically significant and clinically relevant improvements in sexual intercourse and erectile function in patients with ED. Improvement in erectile functioning was related to higher doses for sildenafil and vardenafil. However, higher doses were associated with a greater risk for an adverse effect. Nitrate therapy is a contraindication for therapy with oral PDE-5 inhibitors.

Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence).

The evidence is insufficient to compare the efficacy and adverse effects of different PDE-5 inhibitors for the treatment of ED because only few head-to-head trials are

available. Therefore, individual preferences, ease of use, and cost of medication are reasonable criteria to help select a treatment.

Recommendation 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).

The prevalence of low testosterone varies from 12.5% to 36% in studies of men with ED. However, the evidence is inconclusive about the effectiveness of hormonal treatment in the management of patients with ED, even in patients with low testosterone levels. Trials comparing testosterone (in oral, injection, gel, patch, and cream forms) with placebo in hypogonadal men with ED were small, were of low quality, or reported inconsistent effects on erectile function. Clinicians should individualize decisions to measure hormone levels on the basis of the clinical presentation (for example, decreased libido, premature ejaculation, and fatigue) and physical findings (for example, testicular atrophy and muscle atrophy) that suggest hormonal abnormality.

SUMMARY OF RECOMMENDATIONS AND EVIDENCE

See the **Figure** for a summary of the recommendations and clinical considerations. The **Table** describes the American College of Physicians' guideline grading system.

From the American College of Physicians and University of Pennsylvania, Philadelphia, Pennsylvania; University of Colorado, Aurora, Colorado; Atlantic Health, Morristown, New Jersey; Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, California; and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.

Note: Clinical practice guidelines are “guides” only and may not apply to all patients and all clinical situations. Thus, they are not intended to override clinicians' judgment. All ACP clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.

Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Grant Support: Financial support for the development of this guideline comes exclusively from the American College of Physicians' operating budget.

Potential Conflicts of Interest: *Grants received:* V. Snow (Bristol-Myers Squibb, Centers for Disease Control and Prevention, Novo Nordisk, Merck Vaccines, Boehringer Ingelheim, Wyeth, Sanofi Pasteur), P. Shekelle (Pfizer). *Royalties:* P. Shekelle (Up-to-Date). Any financial and non-financial conflict of interest of the group members were declared, discussed, and resolved.

Requests for Single Reprints: Amir Qaseem, MD, PhD, MHA, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106; e-mail, aqaseem@acponline.org.

Current author addresses are available at www.annals.org.

References

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90. [PMID: 8510302]
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61. [PMID: 8254833]
3. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology. 1999;54:1073-7. [PMID: 10604711]
4. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460-3. [PMID: 10647654]
5. Tsertsvadze A, Yazdi F, Fink HA, MacDonald R, Wilt TJ, Soares-Weiser K, et al. Diagnosis and Treatment of Erectile Dysfunction. AHRQ Evidence Report/Technology Assessment no. 171. Bethesda, MD: Agency for Healthcare Research and Quality; May 2009. AHRQ publication no. 08(09)-E016. Accessed at www.ahrq.gov/downloads/pub/evidence/pdf/erectiledys/erectdys.pdf on 26 May 2009.
6. Aytta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-6. [PMID: 10444124]
7. Wessells H, Joyce GF, Wise M, Wilt TJ. Erectile dysfunction. J Urol. 2007;

- 177:1675-81. [PMID: 17437781]
8. Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis prepared for an American College of Physicians' clinical practice guideline. Ann Intern Med. 2009;151:●●●-●●●.
9. Johnson AR 3rd, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol. 1992;147:1542-3; discussion 1543-4. [PMID: 1593685]
10. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol. 1997;158:1764-7. [PMID: 9334596]
11. Citron JT, Ettinger B, Rubinoff H, Ettinger VM, Minkoff J, Hom F, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol. 1996;155:529-33. [PMID: 8558653]
12. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002;168:615-20. [PMID: 12131320]
13. Martin-Morales A, Meijide F, García N, Artes M, Muñoz A. Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med. 2007;4:440-7. [PMID: 17367439]
14. Acar D, Cayan S, Bozlu M, Akbay E. Is routine hormonal measurement necessary in initial evaluation of men with erectile dysfunction? Arch Androl. 2004;50:247-53. [PMID: 15277002]
15. Earle CM, Stuckey BG. Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy? Urology. 2003;62:727-31. [PMID: 14550452]
16. Rhoden EL, Telöken C, Mafessoni R, Souto CA. Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction? Int J Impot Res. 2002;14:167-71. [PMID: 12058243]
17. Rhoden EL, Telöken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol. 2002;167:1745-8. [PMID: 11912401]
18. Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male. 2002;5:38-46. [PMID: 12040974]
19. Fahmy AK, Mitra S, Blacklock AR, Desai KM. Is the measurement of serum testosterone routinely indicated in men with erectile dysfunction? BJU Int. 1999;84:482-4. [PMID: 10468766]
20. Akpunonu BE, Mutgi AB, Federman DJ, York J, Woldenberg LS. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med. 1994;9:336-8. [PMID: 8077999]
21. Drinka PJ, Voeks S, Bauwens S, Binkley N. Sensitivity and positive predictive value of clinical signs of hypogonadism in elderly men. South Med J. 1993;86:1264-5. [PMID: 8235781]
22. El-Sakka AI, Hassoba HM, Sayed HM, Tayeb KA. Pattern of endocrinal changes in patients with sexual dysfunction. J Sex Med. 2005;2:551-8. [PMID: 16422853]
23. Tsujimura A, Matsumiya K, Miyagawa Y, Takao T, Fujita K, Takada S, et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res. 2005;17:259-63. [PMID: 15616608]
24. Guay AT, Bansal S, Hodge MB. Possible hypothalamic impotence. Male counterpart to hypothalamic amenorrhea? Urology. 1991;38:317-22. [PMID: 1755138]
25. Forsberg L, Gustavii B, Höjerback T, Nilsson A, Olsson AM. One hundred impotent men. Scand J Urol Nephrol. 1990;24:83-7. [PMID: 2356457]
26. Reyes-Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med. 2007;4:1757-62. [PMID: 17087806]
27. El-Sakka AI, Hassoba HM. Age related testosterone depletion in patients with erectile dysfunction. J Urol. 2006;176:2589-93. [PMID: 17085165]
28. Low WY, Khoo EM, Tan HM, Hew FL, Teoh SH. Depression, hormonal status and erectile dysfunction in the aging male: results from a community study in Malaysia. J Mens Health Gend. 2006;3:263-70.
29. Guay A, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med. 2007;4:1046-55. [PMID: 17627749]
30. Zohdy W, Kamal EE, Ibrahim Y. Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction. J Sex Med. 2007;4:797-808. [PMID: 17498110]
31. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams

- RE, et al. Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab.* 2007;92:4241-7. [PMID: 17698901]
32. Kupelian V, Shabsigh R, Travison TG, Page ST, Araujo AB, McKinlay JB. Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study. *J Urol.* 2006;176:2584-8. [PMID: 17085164]
33. El-Sakka AI. Association of risk factors and medical comorbidities with male sexual dysfunctions. *J Sex Med.* 2007;4:1691-700. [PMID: 17081221]
34. Makhlof AA, Mohamed MA, Seftel AD, Niederberger C, Neiderberger C. Hypogonadism is associated with overt depression symptoms in men with erectile dysfunction. *Int J Impot Res.* 2008;20:157-61. [PMID: 17703222]
35. Köhler TS, Kim J, Feia K, Bodie J, Johnson N, Makhlof A, et al. Prevalence of androgen deficiency in men with erectile dysfunction. *Urology.* 2008;71:693-7. [PMID: 18313109]
36. Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, et al. Low levels of androgens in men with erectile dysfunction and obesity. *J Sex Med.* 2008;5:2454-63. [PMID: 18494771]
37. Müezzinoğlu T, Gümüş B, Temeltaş G, Ari Z, Büyüksu C. A relationship of sex hormone levels and erectile dysfunction: which tests should be done routinely? *Yonsei Med J.* 2007;48:1015-9. [PMID: 18159595]
38. Netto Júnior NR, Claro Jde A. The importance of hyperprolactinemia in impotence. *Rev Paul Med.* 1993;111:454-5. [PMID: 8052792]
39. Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with spina bifida is a treatable condition. *J Urol.* 2000;164:958-61. [PMID: 10958716]
40. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. *Am J Psychiatry.* 2001;158:1623-30. [PMID: 11578994]
41. Kongkanand A, Ratana-Olam K, Ruangdilokrat S, Tantiwong A; Thai investigators in ASSESS-2 Study Group. The efficacy and safety of oral sildenafil in Thai men with erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose study. *J Med Assoc Thai.* 2003;86:195-205. [PMID: 12757058]
42. Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. *Diabetes Care.* 2003;26:279-84. [PMID: 12547849]
43. Choi HK, Ahn TY, Kim JJ, Kim SC, Paick JS, Suh JK, et al. A double-blind, randomized- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. *Int J Impot Res.* 2003;15:80-6. [PMID: 12789384]
44. Levinson IP, Khalaf IM, Shaer KZ, Smart DO. Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. *Int J Impot Res.* 2003;15 Suppl 1:S25-9. [PMID: 12825106]
45. DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. *Am J Cardiol.* 2004;93:147-53. [PMID: 14715338]
46. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. *Br J Urol.* 1996;78:257-61. [PMID: 8813924]
47. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *N Engl J Med.* 1998;338:1397-404. [PMID: 9580646]
48. Tan HM, Moh CL, Mendoza JB, Gana T, Albano GJ, de la Cruz R, et al. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 Study Group. *Urology.* 2000;56:635-40. [PMID: 11018621]
49. Meuleman E, Cuzin B, Opsomer RJ, Hartmann U, Bailey MJ, Maytom MC, et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. *BJU Int.* 2001;87:75-81. [PMID: 11121996]
50. Eardley I, Morgan R, Dinsmore W, Yates P, Boolell M. Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. *Br J Psychiatry.* 2001;178:325-30. [PMID: 11282811]
51. Young JM, Bennett C, Gilhooly P, Wessells H, Ramos DE. Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. *Urology.* 2002;60:39-48. [PMID: 12414332]
52. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. *JAMA.* 2003;289:56-64. [PMID: 12503977]
53. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. *Diabet Med.* 1998;15:821-5. [PMID: 9796881]
54. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. *JAMA.* 1999;281:421-6. [PMID: 9952201]
55. Christiansen E, Guirguis WR, Cox D, Osterloh IH; Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. *Int J Impot Res.* 2000;12:177-82. [PMID: 11045912]
56. Olsson AM, Speakman MJ, Dinsmore WW, Giuliano F, Gingell C, Maytom M, et al; Sildenafil Multicentre Study Group. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. *Int J Clin Pract.* 2000;54:561-6. [PMID: 11220982]
57. Chen KK, Hsieh JT, Huang ST, Jian DB, Lin JS, Wang CJ; ASSESS-3 Study Group. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. *Int J Impot Res.* 2001;13:221-9. [PMID: 11494079]
58. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. *Diabetologia.* 2001;44:1296-301. [PMID: 11692178]
59. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. *J Neurol Neurosurg Psychiatry.* 2001;71:371-4. [PMID: 11511713]
60. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. *J Diabetes Complications.* 2004;18:205-10. [PMID: 15207837]
61. Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. *Arch Intern Med.* 2004;164:514-20. [PMID: 15006828]
62. Fowler CJ, Miller JR, Sharief MK, Hussain IF, Stecher VJ, Sweeney M. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2005;76:700-5. [PMID: 15834030]
63. Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. *Am J Kidney Dis.* 2005;45:381-7. [PMID: 15685517]
64. Katz SD, Parker JD, Glasser DB, Bank AJ, Sherman N, Wang H, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. *Am J Cardiol.* 2005;95:36-42. [PMID: 15619391]
65. Abdel-Naser MB, Imam A, Wollina U. Sildenafil citrate significantly improves nocturnal penile erections in sildenafil non-responding patients with psychogenic erectile dysfunction. *Int J Impot Res.* 2004;16:552-6. [PMID: 15116063]
66. Tignol J, Furlan PM, Gomez-Beneyto M, Opsomer R, Schreiber W, Sweeney M, et al. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. *Int Clin Psychopharmacol.* 2004;19:191-9. [PMID: 15201565]
67. Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng LJ, Deriethal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. *Urology.* 2003;62:400-3. [PMID: 12946731]
68. Seibel I, Poli De Figueiredo CE, Telöken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. *J Am Soc Nephrol.* 2002;13:2770-5. [PMID: 12397048]
69. Gómez F, Davila H, Costa A, Acuña A, Wadskier LA, Plua P; Andean Group of Erectile Dysfunction Study. Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. *Int J Impot Res.* 2002;14 Suppl 2:S42-7. [PMID: 12161767]
70. Becher E, Tejada Noriega A, Gomez R, Decia R; Southern Latin America Sildenafil Study Group, Buenos Aires, Argentina. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter,

- flexible-dose escalation study. *Int J Impot Res*. 2002;14 Suppl 2:S33-41. [PMID: 12161766]
71. **Lindsey I, George B, Kettlewell M, Mortensen N.** Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. *Dis Colon Rectum*. 2002;45:727-32. [PMID: 12072621]
72. **Eardley I, Ellis P, Boolell M, Wulff M.** Onset and duration of action of sildenafil for the treatment of erectile dysfunction. *Br J Clin Pharmacol*. 2002;53 Suppl 1:61S-65S. [PMID: 11879261]
73. **Incrocci L, Koper PC, Hop WC, Slob AK.** Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. *Int J Radiat Oncol Biol Phys*. 2001;51:1190-5. [PMID: 11728676]
74. **Olsson AM, Persson CA; Swedish Sildenafil Investigators Group.** Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. *Int J Clin Pract*. 2001;55:171-6. [PMID: 11351770]
75. **Montorsi F, Maga T, Strambi LF, Salonia A, Barbieri L, Scattoni V, et al.** Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. *Urology*. 2000;56:906-11. [PMID: 11113728]
76. **Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC.** Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. *Urology*. 2000;56:477-81. [PMID: 10962319]
77. **Montorsi F, McDermott TE, Morgan R, Olsson A, Schultz A, Kirkeby HJ, et al.** Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. *Urology*. 1999;53:1011-8. [PMID: 10223498]
78. **Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC.** Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. *Urology*. 1999;53:800-5. [PMID: 10197860]
79. **Padma-Nathan H, Steers WD, Wicker PA.** Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. *Sildenafil Study Group*. *Int J Clin Pract*. 1998;52:375-9. [PMID: 9894373]
80. **Albuquerque DC, Miziara LJ, Saraiva JF, Rodrigues US, Ribeiro AB, Wajngarten M.** Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. *Int Braz J Urol*. 2005;31:342-53; discussion 354-5. [PMID: 16137403]
81. **Gingell C, Sultana SR, Wulff MB, Gepi-Attee S.** Duration of action of sildenafil citrate in men with erectile dysfunction. *J Sex Med*. 2004;1:179-84. [PMID: 16422972]
82. **Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, et al.** Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. *Am J Hypertens*. 2004;17:1135-42. [PMID: 15607620]
83. **Glina S, Bertero E, Claro J, Damião R, Faria G, Fregnosi A, et al.** Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in Latin America. *Brazilian Journal of Urology*. 2001;27:148-54.
84. **Heiman JR, Talley DR, Bailen JL, Oskoin TA, Rosenberg SJ, Pace CR, et al.** Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled trial. *BJOG*. 2007;114:437-47. [PMID: 17284249]
85. **Sommer F, Klotz T, Engelmann U.** Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. *Asian J Androl*. 2007;9:134-41. [PMID: 17187165]
86. **McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G.** Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. *J Urol*. 2007;177:1071-7. [PMID: 17296414]
87. **Zinner N.** Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. *J Sex Med*. 2007;4:137-44. [PMID: 17233779]
88. **Orr G, Weiser M, Polliack M, Raviv G, Tadmor D, Grunhaus L.** Effectiveness of sildenafil in treating erectile dysfunction in PTSD patients: a double-blind, placebo-controlled crossover study. *J Clin Psychopharmacol*. 2006;26:426-30. [PMID: 16855464]
89. **Sharma RK, Prasad N, Gupta A, Kapoor R.** Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. *Am J Kidney Dis*. 2006;48:128-33. [PMID: 16797395]
90. **Althof SE, O'Leary MP, Cappelleri JC, Hvidsten K, Stecher VJ, Glina S, et al; International SEAR Study Group.** Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. *J Sex Med*. 2006;3:521-9. [PMID: 16681478]
91. **Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, et al.** Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2006;67:240-6. [PMID: 16566619]
92. **Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK.** Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. *Am J Psychiatry*. 2006;163:494-9. [PMID: 16513872]
93. **O'Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S; United States Self-Esteem and Relationship Questionnaire Study Group.** Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. *J Urol*. 2006;175:1058-62. [PMID: 16469617]
94. **Koulikov D, Fridmans A, Chertin B, Shenfeld O, Farkas A, Spitz IM.** Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male? *J Urol*. 2007;177:2267-71. [PMID: 17509338]
95. **Buranakitjaroen P, Mangklabruks A, Leungwattanakij S, Ngaothamatsan W, Malhotra C, Chee C, et al; Thai-Malaysian-Singapore Erectile Dysfunction Study Group (THAMES Group).** Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. *J Med Assoc Thai*. 2007;90:1100-8. [PMID: 17624203]
96. **Bannowsky A, Schulze H, van der Horst C, Hautmann S, Jünemann KP.** Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. *BJU Int*. 2008;101:1279-83. [PMID: 18284406]
97. **Hong SK, Han BK, Jeong SJ, Byun SS, Lee SE.** Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. *J Urol*. 2007;178:613-6. [PMID: 17570410]
98. **Hundertmark J, Esterman A, Ben-Tovim D, Austin MA, Dougherty M.** The South Australian couples sildenafil study: double-blind, parallel-group randomized controlled study to examine the psychological and relationship consequences of sildenafil use in couples. *J Sex Med*. 2007;4:1126-35. [PMID: 17627725]
99. **Kadioglu A, Grohmann W, Depko A, Levinson IP, Sun F, Collins S.** Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase. *J Sex Med*. 2008;5:726-34. [PMID: 18086165]
100. **Jones LA, Klimberg IW, McMurray JG, Padula R, Tseng LJ, Stecher VJ.** Effect of sildenafil citrate on the male sexual experience assessed with the Sexual Experience Questionnaire: a multicenter, double-blind, placebo-controlled trial with open-label extension. *J Sex Med*. 2008;5:1955-64. [PMID: 18564150]
101. **McCullough AR, Levine LA, Padma-Nathan H.** Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. *J Sex Med*. 2008;5:476-84. [PMID: 18086170]
102. **McCullough AR, Steidle CP, Klee B, Tseng LJ.** Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. *Urology*. 2008;71:686-92. [PMID: 18387397]
103. **McCullough AR, Steidle CP, Kaufman J, Goldfischer ER, Klee B, Carlsson M.** Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction. *Int J Impot Res*. 2008;20:388-95. [PMID: 18528401]
104. **Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, et al.** Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. *Eur Urol*. 2007;52:1768-74. [PMID: 17478034]
105. **Buvat J, Hatzichristou D, Maggi M, Farmer I, Martínez-Jabaloyas JM, Miller PJ, et al.** Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with

- erectile dysfunction. *BJU Int.* 2008;102:1645-50. [PMID: 18710446]
106. **Safarinejad MR.** Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo-controlled, randomized study. *J Urol.* 2009;181:252-8. [PMID: 19013598]
107. **Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B.** Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. *J Urol.* 2009;181:245-51. [PMID: 19013603]
108. **Montorsi F, Padma-Nathan H, Buvat J, Schwaibold H, Beneke M, Ulbrich E, et al; Vardenafil Study Group.** Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. *J Sex Med.* 2004;1:168-78. [PMID: 16422971]
109. **Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T; Vardenafil Diabetes Study Group.** Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. *Diabetes Care.* 2003;26:777-83. [PMID: 12610037]
110. **Valiquette L, Young JM, Moncada I, Porst H, Vézina JG, Stancil BN, et al; Vardenafil Study Group.** Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. *Mayo Clin Proc.* 2005;80:1291-7. [PMID: 16212141]
111. **Nehra A, Grantmyre J, Nadel A, Thibonnier M, Brock G.** Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. *J Urol.* 2005;173:2067-71. [PMID: 15879836]
112. **Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, et al; Patient Response with Vardenafil in Sildenafil Non-Responders (PROVEN) Study Group.** Erectile response with vardenafil in sildenafil nonresponders: a multicenter, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. *BJU Int.* 2004;94:1301-9. [PMID: 15610110]
113. **Nagao K, Ishii N, Kamidono S, Osada T; Vardenafil (Levitra) Clinical Trial Group.** Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. *Int J Urol.* 2004;11:515-24. [PMID: 15242361]
114. **Stief C, Porst H, Sáenz De Tejada I, Ulbrich E, Beneke M; Vardenafil Study Group.** Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. *Int J Clin Pract.* 2004;58:230-9. [PMID: 15117088]
115. **Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H; European Vardenafil Study Group.** The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. *Eur Urol.* 2004;45:634-41; discussion 641. [PMID: 15082207]
116. **Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al.** Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. *J Androl.* 2002;23:763-71. [PMID: 12399521]
117. **Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, et al.** Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. *Eur Urol.* 2001;40:181-8; discussion 189-90. [PMID: 11528196]
118. **Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, et al.** The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. *Int J Impot Res.* 2001;13:192-9. [PMID: 11494074]
119. **Klotz T, Sachse R, Heidrich A, Jockenhövel F, Rohde G, Wensing G, et al.** Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. *World J Urol.* 2001;19:32-9. [PMID: 11289568]
120. **van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M.** Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. *J Sex Med.* 2005;2:856-64. [PMID: 16422810]
121. **Goldstein I, Fisher WA, Sand M, Rosen RC, Mollen M, Brock G, et al; Vardenafil Study Group.** Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. *J Sex Med.* 2005;2:819-32. [PMID: 16422806]
122. **Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, et al; Vardenafil Study Site Investigators.** Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. *Am J Psychiatry.* 2006;163:79-87. [PMID: 16390893]
123. **Edwards D, Hackett G, Collins O, Curram J.** Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naïve men with ED and their partners. *J Sex Med.* 2006;3:1028-36. [PMID: 17100936]
124. **Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, et al; Vardenafil Study Group.** Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. *Eur Urol.* 2006;50:1086-94; discussion 1094-5. [PMID: 16820261]
125. **Mazo E, Gamidov S, Iremashvili V.** The effect of vardenafil on endothelial function of brachial and cavernous arteries. *Int J Impot Res.* 2006;18:464-9. [PMID: 16482199]
126. **Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M.** Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. *J Sex Med.* 2006;3:883-91. [PMID: 16942532]
127. **Ishii N, Nagao K, Fujikawa K, Tachibana T, Iwamoto Y, Kamidono S.** Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. *Int J Urol.* 2006;13:1066-72. [PMID: 16903931]
128. **Demir E, Balal M, Paydas S, Sertdemir Y, Erken U.** Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. *Transplant Proc.* 2006;38:1379-81. [PMID: 16797309]
129. **Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E.** Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. *Eur Urol.* 2008;54:204-10. [PMID: 18395326]
130. **Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O, et al.** Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. *BJU Int.* 2007;100:130-6. [PMID: 17488308]
131. **Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al.** Effect of nightly versus on-demand vardenafil on recovery of erecile function in men following bilateral nerve-sparing radical prostatectomy. *Eur Urol.* 2008;54:924-31. [PMID: 18640769]
132. **Tan HM, Chin CM, Chua CB, Gatchalian E, Kongkanand A, Moh CL, et al.** Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. *Asian J Androl.* 2008;10:495-502. [PMID: 18385912]
133. **Miner M, Gilderma L, Bailen J, Cook D, Dawson K, Stanislaus M, et al.** Vardenafil in men with stable statin therapy and dyslipidemia. *J Sex Med.* 2008;5:1455-67. [PMID: 18373526]
134. **Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H, et al.** An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. *Eur Urol.* 2005;47:846-54; discussion 854. [PMID: 15925082]
135. **Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, et al.** Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. *J Androl.* 2005;26:310-8. [PMID: 15866997]
136. **McMahon CG, Stuckey BG, Lording DW, Wittert GA, Murphy A, Shin J, et al.** A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. *Int J Clin Pract.* 2005;59:143-9. [PMID: 15854188]
137. **Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C; Trial Evaluating the Activity of Tadalafil for Erectile Dysfunction-United States (TREATED-US) Study Group.** Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. *Urology.* 2005;65:353-9. [PMID: 15708052]
138. **Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G.** Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. *Eur Urol.* 2005;47:214-20; discussion 220-2. [PMID: 15661417]
139. **De Rose AF, Gallo F, Carmignani G.** Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. *Int J Impot Res.* 2005;17:76-9. [PMID: 15510191]
140. **Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, et al.**

Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. *BJU Int.* 2004;94:871-7. [PMID: 15476525]

141. Staab A, Tillmann C, Forgue ST, Mackie A, Allerheiligen SR, Rapado J, et al. Population dose-response model for tadalafil in the treatment of male erectile dysfunction. *Pharm Res.* 2004;21:1463-70. [PMID: 15359583]

142. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. *J Urol.* 2004;172:1036-41. [PMID: 15311032]

143. Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. *Eur Urol.* 2004;46:362-9; discussion 369. [PMID: 15306109]

144. Sefel AD, Wilson SK, Knapp PM, Shin J, Wang WC, Ahuja S. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. *J Urol.* 2004;172:652-7. [PMID: 15247754]

145. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. *Urology.* 2003;62:121-5; discussion 125-6. [PMID: 12837435]

146. Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. *Diabetes Care.* 2002;25:2159-64. [PMID: 12453954]

147. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker S, et al. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. *J Sex Med.* 2005;2:685-98. [PMID: 16422827]

148. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. *J Sex Med.* 2005;2:415-25; discussion 425-7. [PMID: 16422874]

149. Chen KK, Jiann BP, Lin JS, Lee SS, Huang ST, Wang CJ, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. *J Sex Med.* 2004;1:201-8. [PMID: 16422975]

150. Rosen RC, Padma-Nathan H, Shabsigh R, Saikali K, Watkins V, Pullman W. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. *J Sex Med.* 2004;1:193-200. [PMID: 16422974]

151. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. *Int J Impot Res.* 2007;19:200-7. [PMID: 16943794]

152. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol.* 2007;177:1401-7. [PMID: 17382741]

153. Saylan M, Khalaf I, Kadioglu A, Shoir KZ, Beheiry A, Wang WC, et al. Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. *Int J Clin Pract.* 2006;60:812-9. [PMID: 16846400]

154. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP 3rd, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. *Int J Impot Res.* 2007;19:95-103. [PMID: 16871272]

155. Yip WC, Chiang HS, Mendoza JB, Tan HM, Li MK, Wang WC, et al. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. *Asian J Androl.* 2006;8:685-92. [PMID: 16855765]

156. Guo YL, Zhu JC, Pan TM, Ding Q, Wang YX, Cheong NF, et al. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. *Int J Urol.* 2006;13:721-7. [PMID: 16834650]

157. Nagao K, Kimoto Y, Marumo K, Tsujimura A, Vail GM, Watts S, et al. Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. *Urology.* 2006;68:845-51. [PMID: 17070365]

158. Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. *Int J Radiat Oncol Biol Phys.* 2006;66:439-44. [PMID: 16965992]

159. Choi HK, Kim JJ, Kim SC, Suh J, Park YK, Choi S, et al. A randomised,

double-blind, parallel, placebo-controlled study of the efficacy and safety of Tadalafil administered on-demand to men with erectile dysfunction in Korea. *Taehan Pinyogikwa Hakhoe Chapchi.* 2006;47:852-58.

160. Bocchio M, Pelliccione F, Passaquale G, Mihalca R, Necozone S, Desideri G, et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. *Atherosclerosis.* 2008;196:313-9. [PMID: 17150221]

161. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. *Diabet Med.* 2008;25:138-46. [PMID: 18290855]

162. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. *J Sex Med.* 2008;5:946-53. [PMID: 18221288]

163. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. *BJU Int.* 2005;96:1323-32. [PMID: 16287454]

164. von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. *Eur Urol.* 2004;45:499-507; discussion 507-9. [PMID: 15041116]

165. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. *Clin Ther.* 2003;25:2709-23. [PMID: 14693299]

166. Tolrà JR, Campaña JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. *J Sex Med.* 2006;3:901-9. [PMID: 16942534]

167. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. *J Sex Med.* 2008;5:2672-80. [PMID: 18638004]

168. Paick JS, Choi HK, Kim SC, Ahn TY, Kim JJ, Park JK, et al. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. *Asian J Androl.* 2008;10:791-8. [PMID: 18645683]

169. Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. *Urology.* 2005;66:1080-5. [PMID: 16286128]

170. Perimenis P, Markou S, Gyftopoulos K, Giannitsas K, Athanasopoulos A, Liatsikos E, et al. Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. *Andrologia.* 2004;36:106-10. [PMID: 15206909]

171. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. *BJU Int.* 2004;93:1271-5. [PMID: 15180621]

172. Perimenis P, Gyftopoulos K, Giannitsas K, Markou SA, Tsota I, Chrysanthopoulou A, et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. *Int J Impot Res.* 2004;16:2-7. [PMID: 14963464]

173. Pavone C, Curto F, Anello G, Serretta V, Almasio PL, Pavone-Macaluso M. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. *J Urol.* 2004;172:2347-9. [PMID: 15538264]

174. Porst H, Behre HM, Jungwirth A, Burkart M. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction—an open, randomized cross-over study with flexible dosing. *Eur J Med Res.* 2007;12:61-7. [PMID: 17369119]

175. Melnik T, Abdo CH. Psychogenic erectile dysfunction: comparative study of three therapeutic approaches. *J Sex Marital Ther.* 2005;31:243-55. [PMID: 16020142]

176. Perimenis P, Karkoulas K, Konstantinopoulos A, Perimeni PP, Katsenis G, Athanasopoulos A, et al. Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a comparative study of their efficacy and safety and the patient's satisfaction with treatment. *Asian J*

- Androl. 2007;9:259-64. [PMID: 17334593]
177. **Ugarte F, Hurtado-Coll A.** Comparison of the efficacy and safety of sildenafil citrate (Viagra) and oral phenolamine for the treatment of erectile dysfunction. *Int J Impot Res.* 2002;14 Suppl 2:S48-53. [PMID: 12161768]
178. **Choppin A, Blue DR, Hegde SS, Gennevois D, McKinnon SA, Mokatriin A, et al.** Evaluation of oral ro70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. *Int J Impot Res.* 2001;13:157-61. [PMID: 11525314]
179. **Kaplan SA, Gonzalez RR, Te AE.** Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. *Eur Urol.* 2007;51:1717-23. [PMID: 17258855]
180. **Diamond LE, Earle DC, Garcia WD, Spana C.** Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. *Urology.* 2005;65:755-9. [PMID: 15833522]
181. **Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F.** Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. *Curr Med Res Opin.* 2004;20:1377-84. [PMID: 15383186]
182. **Dunzendorfer U, Behm A, Dunzendorfer E, Dunzendorfer A.** Drug combinations in the therapy of low response to phosphodiesterase 5 inhibitors in patients with erectile dysfunction. *In Vivo.* 2002;16:345-8. [PMID: 12494876]
183. **Bank AJ, Kelly AS, Kaiser DR, Crawford WW, Waxman B, Schow DA, et al.** The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. *Vasc Med.* 2006;11:251-7. [PMID: 17390549]
184. **Safarinejad MR.** Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. *Int J Impot Res.* 2006;18:550-8. [PMID: 16625231]
185. **Herrmann HC, Levine LA, Macaluso J Jr, Walsh M, Bradbury D, Schwartz S, et al.** Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. *J Sex Med.* 2006;3:303-8. [PMID: 16490024]
186. **Haren M, Chapman I, Coates P, Morley J, Wittert G.** Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. *Age Ageing.* 2005;34:125-30. [PMID: 15596419]
187. **Seftel AD, Mack RJ, Secrest AR, Smith TM.** Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. *J Androl.* 2004;25:963-72. [PMID: 15477371]
188. **Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H.** Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. *J Urol.* 2004;172:658-63. [PMID: 15247755]
189. **Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G.** Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. *Urology.* 2004;63:641-6. [PMID: 15072869]
190. **Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A.** Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. *Clin Endocrinol (Oxf).* 2003;58:632-8. [PMID: 12699447]
191. **Clopper RR, Voorhess ML, MacGillivray MH, Lee PA, Mills B.** Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. *Psychoneuroendocrinology.* 1993;18:149-61. [PMID: 8493299]
192. **Boyanov MA, Boneva Z, Christov VG.** Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. *Aging Male.* 2003;6:1-7. [PMID: 12809074]
193. **Rabkin JG, Wagner GJ, Rabkin R.** A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. *Arch Gen Psychiatry.* 2000;57:141-7; discussion 155-6. [PMID: 10665616]
194. **Shamloul R, Ghanem H, Fahmy I, El-Meiegy A, Ashoor S, Elnashaar A, et al.** Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. *J Sex Med.* 2005;2:559-64. [PMID: 16422854]
195. **Schiavi RC, White D, Mandeli J, Levine AC.** Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. *Arch Sex Behav.* 1997;26:231-41. [PMID: 9146812]
196. **Yassin AA, Saad F, Diede HE.** Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. *Andrologia.* 2006;38:61-8. [PMID: 16529577]
197. **Seidman SN, Roose SP.** The sexual effects of testosterone replacement in depressed men: randomized, placebo-controlled clinical trial. *J Sex Marital Ther.* 2006;32:267-73. [PMID: 16809253]
198. **Gomaa AA, Hamed HA.** Improvement of sexual function in partial testosterone-deficient ageing men treated with cream containing testosterone and vasoactive agents. *J Mens Health Gen.* 2006;3:47-55.
199. **Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al.** Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. *Int J Androl.* 2006;29:381-91. [PMID: 16390499]
200. **Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, et al.** Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. *Int J Impot Res.* 2007;19:411-7. [PMID: 17538639]
201. **Margo CE, French DD.** Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. *Am J Ophthalmol.* 2007;143:538-9. [PMID: 17317413]
202. **McEvoy GK.** AHFS Drug Information. Bethesda, MD: American Soc of Health-System Pharmacists; 2008.

Current Author Addresses: Drs. Qaseem and Snow: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.
Dr. Denberg: 12631 East 17th Avenue, B180, Academic Office 1, Aurora, CO 80045.
Dr. Casey: 475 South Street, PO Box 1905, Morristown, NJ 07962.
Dr. Forcica: 3615 Chestnut Street, Philadelphia, PA 19104.
Dr. Owens: 117 Encina Commons, Stanford, CA 94305.
Dr. Shekelle: 1776 Main Street, Santa Monica, CA 90401.

Author Contributions: Conception and design: A. Qaseem, V. Snow, D.E. Casey Jr., D.K. Owens.

Analysis and interpretation of the data: A. Qaseem, D.E. Casey Jr., M.A. Forcica, D.K. Owens.
Drafting of the article: A. Qaseem, V. Snow, T.D. Denberg, D.E. Casey Jr., M.A. Forcica, D.K. Owens.
Critical revision of the article for important intellectual content: A. Qaseem, V. Snow, T.D. Denberg, D.E. Casey Jr., M.A. Forcica, D.K. Owens, P. Shekelle.
Final approval of the article: A. Qaseem, V. Snow, T.D. Denberg, D.E. Casey Jr., M.A. Forcica, D.K. Owens, P. Shekelle.
Statistical expertise: A. Qaseem.
Administrative, technical, or logistic support: A. Qaseem.
Collection and assembly of data: A. Qaseem.